Urodynamics in patients with multiple sclerosis: A consensus statement from a urodynamic experts working group.
diagnosis
lower urinary tract symptoms
multiple sclerosis
risk factors
urodynamics
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
27
10
2019
accepted:
29
10
2019
pubmed:
21
11
2019
medline:
21
10
2020
entrez:
21
11
2019
Statut:
ppublish
Résumé
Urodynamics (UDS) is often indicated for multiple sclerosis (MS) patients either at presentation to specialized medical centers or after failure of conservative management of lower urinary tract dysfunction (LUTD). However, the ideal moment and context to indicate this exam in this group of patients remain controversial. We aimed to establish a consensus panel to address the role of UDS in MS patients. A panel representing urology, rehabilitation medicine, and neurology skilled in neuro-urology participated in a consensus-forming project using a Delphi method to reach consensus on the role of UDS in MS patients. In total, five experts participated. All panelists participated in the four phases of the consensus process. Consensus was reached if ≥70% of the experts agreed on recommendations. To facilitate a common understanding among all experts, a face-to-face consensus meeting was held in Florence in September 2017 and then with a follow-up teleconference in March 2018. By the end of the Delphi process, formal consensus was achieved for 100% of the items and an algorithm was then developed in a face-to-face meeting in Philadelphia in August 2018. The final expert opinion recommendations were approved by the unanimous consensus of the panel. UDS represents an important diagnostic tool for MS patients and is particularly useful to evaluate the pattern of LUT dysfunction in high-risk patients. There is a lack of high-evidence level studies to support an optimal urodynamic long-term follow-up protocol.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-82Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Chancellor MB, Blaivas JG. Urological and sexual problems in multiple sclerosis. Clin Neurosci. 1994;2(3-4):189-195.
Giannantoni A, Scivoletto G, Di Stasi SM, et al. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil. 1999;80(4):437-441.
Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol. 2016;69(2):324-333.
Gajewski JB, Schurch B, Hamid R, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 2018;37(3):1152-1161.
Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653
Abrams P, Cardozo L, Wagg A, Wein AE. Incontinence. 6th. Bristol, UK: International Continence Society; 2017.
Clark R, Welk B. Patient reported outcome measures in neurogenic bladder. Transl Androl Urol. 2016;5(1):22-30.
Costa P, Costa P, Perrouin-Verbe B, et al. Quality of Life in spinal cord injury patients with urinary difficulties. Eur Urol. 2001;39(1):107-113.
Patel DP, Elliott SP, Stoffel JT, Brant WO, Hotaling JM, Myers JB. Patient reported outcomes measures in neurogenic bladder and bowel: a systematic review of the current literature. Neurourol Urodyn. 2016;35(1):8-14.
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646-652.
Dillon BE, Seideman CA, Lee D, Greenberg B, Frohman EM, Lemack GE. A surprisingly low prevalence of demonstrable stress urinary incontinence and pelvic organ prolapse in women with multiple sclerosis followed at a tertiary neurogenic bladder clinic. J Urol. 2013;189(3):976-979.
Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J. 2009;85(5):552-559.
Rakusa M, Murphy O, McIntyre L, et al. Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. Eur J Neurol. 2013;20(3):448-452.
Tannenbaum C, Corcos J. Outcomes in urinary incontinence: reconciling clinical relevance with scientific rigour. Eur Urol. 2008;53(6):1151-1161.
Bright E, Drake MJ, Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011;30(3):348-352.
Quinn P, Goka J, Richardson H. Assessment of an electronic daily diary in patients with overactive bladder. BJU Int. 2003;91(7):647-652.
Bright E, Cotterill N, Drake M, Abrams P. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol. 2014;66(2):294-300.
de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915-928.
Ghezzi A, Carone R, Del Popolo G, et al. Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurol Sci. 2011;32(6):1223-1231.
Compston A, Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502-1517.
Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. The Lancet Neurology. 2015;14(7):720-732.
Phe V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275-288.
Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169(4):1384-1387.
Grasso MG, Pozzilli C, Anzini A, Salvetti M, Bastianello S, Fieschi C. Relationship between bladder dysfunction and brain MRI in multiple sclerosis. Funct Neurol. 1991;6(3):289-292.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983;33:1444-1444.
Lawrenson R, Wyndaele JJ, Vlachonikolis I, Farmer C, Glickman S. Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology. 2001;20(2):138-143.
NICE. Urinary incontinence in neurological disease (CG148). 2012.
Rosier P, Schaefer W, Lose G, et al. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36:1243-1260.
Vainrib M, Reyblat P, Kong WG, Ginsberg DA. Supine and upright urodynamic evaluation of incontinent ileovesicostomy in wheelchair-bound adults with neurogenic bladder. Spinal Cord. 2013;51(8):634-636.
Hermieu J. Recommendations for the urodynamic examination in the investigation of non-neurological female urinary incontinence. Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2007;17:1264-1284.
Suzuki Bellucci CH, Wöllner J, Gregorini F, et al. Neurogenic lower urinary tract dysfunction--do we need same session repeat urodynamic investigations? J Urol. 2012;187(4):1318-1323.
Gallien P, Robineau S, Nicolas B, Le Bot MP, Brissot R, Verin M. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil. 1998;79(3):255-257.
Onal B, Siva A, Buldu I, Demirkesen O, Cetinel B. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol. 2009;35(3):326-333.
Tadayyon F, Etemadifar M, Bzeih H, et al. Association of urodynamic findings in new onset multiple sclerosis with subsequent occurrence of urinary symptoms and acute episode of disease in females. J Res Med Sci. 2012;17(4):382-385.
Wiedemann A, Kaeder M, Greulich W, et al. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? An analysis of 100 prospective cases. World J Urol. 2013;31(1):229-233.
Çetinel B, Tarcan T, Demirkesen O, et al. Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report. Neurourol Urodyn. 2013;32(8):1047-1057.
Guinet-Lacoste AVD, Le Breton F, Peyrat L, Amarenco G. Incontinence urinaire à l'effort et sclérose en plaques. Annals of Physical and Rehabilitation Medicine. 2014;57:e308-e309.
Murphy AM, Bethoux F, Stough D, Goldman HB. Prevalence of stress urinary incontinence in women with multiple sclerosis. Int Neurourol J. 2012;16(2):86-90.
Mahajan ST, James R, Frasure H. Pelvic floor disorders and multiple sclerosis: are patients satisfied with their care? Int J MS Care. 2014;16(1):20-25.
Massot C, Khenioui H, Agnani O, Guyot MA, Hautecoeur P, Donze C. Stress urinary incontinence in women with multiple sclerosis. Int Neurourol J. 2016;20(3):224-231.
Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099-1109.
Chen JS, Chang CH, Yang WH, Kao YH. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int. 2012;110:E896-E901.
Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol. 2009;55(2):461-471.
Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422-1427.
Lemack GE, Hawker K, Frohman E. Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology. 2005;65(5):854-857.
Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196-200.
Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006 Mar;49(3):528-535.
Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiß C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn. 2006;25(2):110-115.
Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344-1349.
Herschorn S, Gajewski J, Ethans K, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229-2235.
Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742-750.
Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(8):1109-1115.
Kennelly M, Dmochowski R, Schulte-Baukloh H, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36(2):368-375.
Leitner L, Guggenbühl-Roy S, Knüpfer SC, et al. More than 15 years of experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol. 2016;70(3):522-528.
Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37(5):642-648.
Sliwa JA, Bell HK, Mason KD, Gore RM, Nanninga J, Cohen B. Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Arch Phys Med Rehabil. 1996;77(3):247-251.
Fakas M, Souli M, Koratzanis G, Karageorgiou C, Giamarellou H, Kanellakopoulou K. Effects of antimicrobial prophylaxis on asymptomatic bacteriuria and predictors of failure in patients with multiple sclerosis. J Chemother. 2010;22(1):36-43.